Stonepine Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Stonepine Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,264	Closed	-$70.7K	–	74
2024 Q4	$70.7K	Sell	23,264 -796,736	-97%	-$3.47M	0.06%	51
2024 Q3	$4.26M	Sell	820,000 -1,980,000	-71%	-$9.84M	2.69%	10
2024 Q2	$7.2M	Buy	2,800,000 +823,658	+42%	+$2.81M	6.57%	5
2024 Q1	$9.72M	Buy	+1,976,342	New	+$11.7M	7.71%	5

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Stonepine Capital Management's RVNC Position: Q1 2025 in Review

Stonepine Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 23,264 shares — an estimated $70.7K sold.

Stonepine Capital Management first reported a position in RVNC in Q1 2024 and held it in 4 quarters. The position peaked at $9.72M in Q1 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Stonepine Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Stonepine Capital Management sold 23,264 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $70.7K.
Stonepine Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2024 and held it in 4 quarters.
Stonepine Capital Management's Revance Therapeutics, Inc. position peaked at $9.72M in Q1 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.